Since the UK’s decision to leave the EU was voted through, there have been many sceptics who have tried to claim that this result will be damaging for scientific research in the UK. However, the opposite could actually be true, as we become free from stringent EU regulations.
The EU Clinical Trials Directive took effect in 2004, which centralised large parts of the clinical trials process, and further regulations were set to be implemented in 2018. A recent report from the Commons Science and Technology Committee stated that these changes had ‘significantly increased the administrative burden and cost of running academic clinical trials and saw a reduction in trials taking place in Europe’. Therefore, the vote to leave the EU could actually benefit the UK’s pharma industry.
Held Back by the EU
Since the new directive came into effect there have been more regulatory issues for pharmaceutical companies to negotiate, which has resulted in a more inefficient system and numerous delays in the approval process. Overall this has led to a reduction in the UK’s clinical trial industry. However even with this news lots of people are still happy to use Paid Medical Trials to get some extra money to help medical research. trials 4 us offer paid medical trials with a great selection process if you do want to find out more about it.
As a result of the EU directive, some of the groundbreaking trials which used leading clinical trial services had to be stopped to prevent academic institutions going against the regulations. Some leading researchers believe that this has led to unnecessary deaths amongst patients.
There were also significant costs associated with implementing the regulations and this even affected the large pharma companies. As well as a reduction in funding, their bureaucratic approach gave a priority to certain projects and made it increasingly difficult for others to receive grants.
Innovative UK Research
The conservative EU directive controls the risks too strictly compared to the UK’s clinical trials industry, which has historically been more liberal in its approach. This enabled the sector to operate at a quicker pace, though still within the ethical guidelines, bringing in high quality staff. For instance, researchers could look into using old drugs for new purposes, but the directive put a stop to this.
Many within the industry hope that post-Brexit there will be a more research-led approach to clinical trials, which will bring greater creativity and result in innovative breakthroughs that save lives and make the UK’s research sector one of the best in the world.